Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial
Carolina Digital Repository (University of North Carolina at Chapel Hill) · 22.05.2024
DOI: 10.17615/v4zy-1y17 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 22.05.2024. Verfasst von Rodica Pop‐Busui und 23 weiteren Autor:innen. Die Arbeit wurde bisher 44-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied.
Objective
To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. Design, Setting, and Participants: This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications.
Interventions
Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). Main Outcomes and Measures: The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180 mg/dL, time with glucose level at greater than 250 mg/dL, and mean glucose level at 8 months.
Results
Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4% [95% CI, -0.8% to -0.1%]; P =.02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180 mg/dL was 59% vs 43% (adjusted difference, 15% [95% CI, 8% to 23%]; P
Schlagwörter
Zitieren
APA
Pop‐Busui, R., Umpierrez, G. E., BIGGS, W. C., Orozco, I. J., Q.T, N., Philis‐Tsimikas, A., R.M, B., Price, D. A., Buse, J. B., K.J, R., Beck, R. W., Calhoun, P. M., Bailey, R. J., D, K., Aleppo, G., Young, L., A.L, P., K.J, L., Bhargava, A., …, & T, M. (2024). Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/v4zy-1y17
Vancouver
Pop‐Busui R, Umpierrez GE, BIGGS WC, Orozco IJ, Q.T N, Philis‐Tsimikas A, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2024. doi:10.17615/v4zy-1y17
BibTeX
@article{PopBusui2024,
author = {Pop‐Busui, Rodica and Umpierrez, Guillermo E. and BIGGS, WILLIAM C. and Orozco, Ian J. and Q.T, Nguyen and Philis‐Tsimikas, Athena and R.M, Bergenstal and Price, David Anthony and Buse, John B. and K.J, Ruedy and Beck, Roy W. and Calhoun, Peter M. and Bailey, Ryan J. and D, Kruger and Aleppo, Grazia and Young, Laura and A.L, Peters and K.J, Lucas and Bhargava, Anuj and McGill, J.B. and W.H, Polonsky and Davis, Georgia M. and S, Bao and T, Martens},
title = {Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial},
journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
year = {2024},
doi = {10.17615/v4zy-1y17}
}
EUVIMED